课题基金 / 基金详情

HPV: BIOLOGY, CLINICAL SIGNIFICANCE AND EPIDEMIOLOGY

HPV: BIOLOGY, CLINICAL SIGNIFICANCE AND EPIDEMIOLOGY
HPV:生物学、临床意义和流行病学
批准号:
3094025
负责人:
JAMES K. MCDOUGALL
金额:
$141.96万
依托单位国家:
美国
项目类别:
财政年份:
1987
资助国家:
美国
项目状态:
已结题
起止时间:
1987-04-10 至 1995-07-31

项目摘要

项目成果

JAMES K. MCDOUGALL的其他基金

相似基金

相关文献

中文摘要
翻译
该计划项目是多学科研究的延续。 人乳头瘤病毒在肛门生殖道癌病因中的作用。这个 个别项目涉及这些疾病的流行病学,东道主 从发病机制和免疫机制方面的反应和 表达乳头瘤病毒基因的细胞生物学。四个项目是 提议:第一个项目(0001)涉及免疫问题 对乳头瘤病毒感染的反应和免疫调节的作用 进展为癌症。第二个项目(0002)检查 乳头瘤病毒基因对细胞增殖的影响 并将决定辅因子通过哪些机制 有助于恶变的进展。第三部作品(0004) 继续进行病例对照研究,调查人乳头瘤病毒在 肛门生殖器癌的发展。第四个项目(0006)涉及一个 人乳头瘤病毒阳性病例预后评估 细胞学和分子杂交。这些项目得到了四个项目的支持 将提供分子生物学、组织学和细胞学的核心 支持以及生物统计分析和行政监督。
英文摘要
This program project is a continuation of multidisciplinary studies of the role of human papillomaviruses in the etiology of anogenital cancers. The individual projects address the epidemiology of these diseases, the host response in terms of pathogenesis and mechanisms of immunity and the biology of cells expressing papillomavirus genes. Four projects are proposed: The first project (0001) addresses the questions of immune response to papillomavirus infection and the role of immune modulation in progression to cancer. The second project (0002) examines the characteristics of cells proliferating in response to papillomavirus gene expression and will determine the mechanisms through which cofactors contribute to progression to malignancy. The third project (0004) continues case-control studies investigating the role of HPV in the development of anogenital cancers. The fourth project (0006) deals with an evaluation of prognosis of cases previously identified as HPV positive by cytology and molecular hybridization. The projects are supported by four cores which will provide molecular biological, histological and cytological support as well as biostatistical analysis and administrative oversight.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VIROLOGIC/GENETIC FACTORS OF HPV NEOPLASMS
CORE--MOLECULAR BIOLOGY LABORATORY
CORE--MOLECULAR BIOLOGY LABORATORY
THE ONCOGENIC POTENTIAL OF HUMAN PAPILLOMAVIRUS
海外基金